Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Iron-Busting drug tested as Parkinson's slower

NCT ID NCT02655315

Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a drug called deferiprone, which removes extra iron from the body, could slow down Parkinson's disease. 372 adults with early Parkinson's took either the drug or a placebo for 9 months. The goal was to see if the drug could reduce both movement and non-movement symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

372 people

The number who actually took part.

Started

Feb 2016

Finished

Sep 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients 2. Parkinson's disease diagnosed according United Kingdom Parkinson's disease Society Brain Bank Clinical Diagnostic Criteria and based on the presence of at least two of the three cardinal features of the disease (rest tremor, bradykinesia and rigidity). If rest tremor is not present, subjects must have unilateral onset of symptoms. 3. Treatment-naïve, i.e. the best population for assessing a disease-modifying effect without the interaction of dopaminergic treatment (no dopaminergic agonists, L-dopa, anticholinergics, monoamine oxidase B inhibitors (e.g. rasagiline) or deep brain stimulation). 4. Patients covered by a Health Insurance System in countries where required by law 5. Written informed consent dated and signed prior to the beginning of any procedures related to the clinical trial Exclusion Criteria: 1. Disease duration greater than 18 months. 2. Patients with high frequency of comorbidity or vital risks that may reasonably impair life expectancy 3. Subject with handicap required dopaminergic treatment at the inclusion and therefore likely not to bear 9 months without symptomatic treatment 4. Hoehn and Yahr stage 3 or more. 5. Significant cognitive impairment (a Mini Mental State Examination score \<24 or an equivalent impairment on a similar scale) or dementia diagnosed in accordance with the Movement Disorders Society criteria (Emre et al., 2007). 6. Atypical or secondary parkinsonism (supranuclear palsy, multisystem atrophy, etc.) or anomalies on MRI suggestive of vascular involvement or significant cortical or subcortical atrophy (i.e. atypical for Parkinson's Disease). 7. Progressing axis I psychiatric disorders (psychosis, hallucinations, substance addiction, bipolar disorder, or severe depression), in accordance with the Diagnostic and Statistical Manual of Mental Disorders. 8. Subjects undergoing brain stimulation. 9. Positive Human Immunodepression Virus serology. 10. Hypersensitivity to deferiprone. 11. Patients with agranulocytosis or with a history of agranulocytosis. 12. Patients taking a treatment at risk of agranulocytosis (clozapine, Closaril®/Leponex®). 13. Patients with anaemia (regardless of the latter's aetiology) or a history of another haematological disease. Haemochromatosis is not an exclusion criterion. 14. Pregnant or breastfeeding women or women of childbearing potential not taking highly effective contraception. 15. Kidney or liver failure. 16. Other serious diseases. 17. Inability to provide informed consent. 18. Participation in another clinical trial with investigational medicinal product within 3 months prior to inclusion in the study 19. Patient who has suffered mild or moderate depressive episode and isn't in remission and on a stable medication for at least 8 weeks 20. Patient \> 130k Exclusion criteria for the biomarker study and the ancillary study (i) Magnetic Resonance Imaging: * Subjects for whom Magnetic Resonance Imaging is contraindicated (metal objects in the body, severe claustrophobia, pacemaker, incompatible surgical material). * Very severe rest tremor, which could induce Magnetic Resonance Imaging artefacts. (ii) Lumbar puncture: * Blood coagulation disorders, antiplatelet drugs or anticoagulants. * Intracranial hypertension. (iii) Contraindications to nitrous oxide: * Ventilation with Fraction of inspired Oxygen \>50%, emphysema or pneumothorax * Altered states of consciousness, non-cooperative patient (need to stop the nitrous oxide)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • AP-HP, Hôpital Pitié-Salpêtrière

    Paris, France

  • Acadamic central center, Amsterdam

    Amsterdam, Netherlands

  • CHU Pellegrin

    Bordeaux, France

  • CHU de Strasbourg, Hôpital de Hautepierre

    Strasbourg, France

  • CHU la TIMONE

    Marseille, France

  • Cambridge University Hospital

    Cambridge, United Kingdom

  • Centro Hospitalar Lisboa Norte

    Lisbon, Portugal

  • Centro Hospitalar do Alto Ave

    Guimarães, Portugal

  • Centro Hospitalar e universitario de Coimbra

    Coimbra, Portugal

  • Charles University

    Prague, Czechia

  • Christian-albrechts universität zu kiel

    Kiel, Germany

  • Chu Purpan

    Toulouse, France

  • Hospital Clinic Universitari de Barcelona

    Barcelona, Spain

  • Hospital de Bellvitge

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hôpital Montpied

    Clermont-Ferrand, France

  • Hôpital Salengro, CHRU

    Lille, France

  • Hôpital Wertheimer

    Bron, France

  • Klinik und Poliklinik für Neurologie der Universitätsmedizin Rostock

    Rostock, Germany

  • Medizinische Universitat Innsbruck

    Innsbruck, Austria

  • Newcastle University

    Newcastle, United Kingdom

  • Radboud university medical center

    Nijmegen, Netherlands

  • University Hospital, Saarland University

    Homburg, Germany

  • University of Glasgow

    Glasgow, United Kingdom

  • Univerzita Karlova V Praze

    Prague, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.